RE:RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus " That same IPO paperwork shed more light on the end of Turnstone’s deal with AbbVie, which paid $90 million to work with the biotech in 2017 but terminated the partnership in 2021. A separate $80 million upfront development deal with Takeda only lasted until 2022 with a remaining discovery pact with the Japanese Big Pharma ending in 2023.
Against that backdrop, Turnstone’s IPO is a reminder that biotech listings are beginning to bubble back up after a quiet 2022. It comes just a week after Paragon spinout Apogee Therapeutics and Sagimet Biosciences both landed on the Nasdaq with offerings that overshot expectations. Turnstone sits closer to the more modest $85 million that Sagimet mustered for its own IPO as opposed to the hefty $300 million Apogee brought in."
https://www.fiercebiotech.com/biotech/apogee-sagimet-overshoot-ipo-expectation-both-biotechs-land-nasdaq